Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
wire - news in brief
Category
Results 51 - 100 of 313.
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
Bern Center for Precision Medicine inaugurated
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
Santhera Pharmaceuticals and the University of Basel's Biozentrum announce their collaboration to advance gene therapy research for the treatment of congenital muscular dystrophy.
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
A nationwide systematic survey of 97 organisations carried out by Swiss TPH shows that authorities, hospitals, institutions and organisations in Switzerland have long been committed to efforts against the flu.
Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc
Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review Roche and Spark Therapeutics, Inc.
Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review Roche and Spark Therapeutics, Inc.
A system developed by EPFL spin-off TreaTech can turn sludge from wastewater treatment plants into mineral salts - which could be used in fertilizer, for example - and biogas.
In Granada, the European particle physics community prepares decisions for the future of the field
Geneva and Granada. The European particle physics community is meeting this week in Granada, Spain, to discuss the roadmap for the future of the discipline.
Geneva and Granada. The European particle physics community is meeting this week in Granada, Spain, to discuss the roadmap for the future of the discipline.
Novartis data at AAN show Gilenya is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
EPFL's Digital Epidemiology Lab held its first food DNA sequencing workshop last Saturday, in association with SwissDeCode and Hackuarium.
Novartis data at AAN show Mayzent’s positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
New AveXis data at AAN showed long-term durability of Zolgensma in patients with spinal muscular atrophy (SMA) Type 1
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with Zolge
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with Zolge
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting
In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New data from the dose-finding Part 1 of SUNFISH reinforce risdiplam as a promising investigational therapy for people with Type 2 or 3 spinal muscular atrophy No treatment-related safety findings leading to withdrawal seen to date in risdiplam trials Roche today announ
In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New data from the dose-finding Part 1 of SUNFISH reinforce risdiplam as a promising investigational therapy for people with Type 2 or 3 spinal muscular atrophy No treatment-related safety findings leading to withdrawal seen to date in risdiplam trials Roche today announ
In cooperation with Empa, the Austrian Space Forum (ÖFW) is developing the "Serenity" space suit - a prototype for a Mars suit.
FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma in broad spectrum of spinal muscular atrophy (SMA) patients
Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)
Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)
Novartis to highlight extensive long-term safety and efficacy data of Aimovig across the spectrum of migraine at AAN
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
Moving people and technology
On 2 and 3 May 2020 ' exactly one year from now ' the Swiss Arena will open its doors for the next edition of the Cybathlon.
On 2 and 3 May 2020 ' exactly one year from now ' the Swiss Arena will open its doors for the next edition of the Cybathlon.
New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions
Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple scl
Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple scl
New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in re
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in re
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy